All In Biotech

Drug Trial Radar · NCT03145220

Immunomodulation of EA-230 Following On-pump Coronary Artery Bypass Grafting (CABG)

Randomized Double Blind Placebo-controlled Phase II Study on the Effects of EA-230 on the Systemic Inflammatory Response Following On-pump Cardiac Surgery

Last checked: Nov 19, 2026Latest source record: Jun 26, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

180

Actual

Start

Jun 2016

Primary completion

Oct 2018

Study completion Oct 2018

Sponsor

Lead sponsor
Radboud University Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Exponential Biotherapies Inc.
First posted
May 9, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

EA-230 is a newly developed synthetic compound with anti-inflammatory properties, it is a linear tetrapeptide derived from the human chorionic gonadotropin hormone (hCG). Recently, its immunomodulatory effects in humans were confirmed in a phase I trial and an optimal dose was established. To establish this anti-inflammatory effect in a selected patient population and assess clinical outcome, a combined phase IIa/IIb trial will be conducted with patients undergoing cardiac surgery.

Conditions

  • Systemic Inflammatory Response Syndrome
  • Coronary Artery Bypass Grafting

Interventions

  • EA-230Drug

    Active intervention

  • Placebo (NaCl)Other

    Placebo intervention

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability (treatment related (serious) adverse events)Time frame: Total (serious) adverse events related to treatment at day 90 after treatment
  2. Interleukin-6 (IL-6)Time frame: 1 day: at baseline, start of the cardiopulmonary bypass (CPB), stop of CPB, 2h after stop of CPB, 4h after stop of CPB, 6h after stop of CPB and first post-operative day.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Intensive care, research unit, Radboud University Medical Centre

    Nijmegen, Gelderland, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.